32-4600

antibody from Invitrogen Antibodies

Targeting: SRSF1 ASF, MGC5228, SF2, SF2p33, SFRS1, SRp30a

Provider product page for 32-4600

Western blot

Immunocytochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [27]
Comments [0]
Validations
Western blot [1]
Immunocytochemistry [1]
Other assay [19]

Submit

Product number: 32-4600 - Provider product page
Provider: Invitrogen Antibodies
Product name: SRSF1 Monoclonal Antibody (103)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Reactivity: Human, Mouse, Rat
Host: Mouse
Isotype: IgG
Antibody clone number: 103
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: -20°C

SRSF1 protein structure - 32-4600 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Sources of cell-to-cell variability in fractional isoform abundance. ( A ) Schematic of sources of cell-to-cell variability in FIA. ( B - D ) Fluctuations in synthesis rate are a source of FIA variability, particularly for MKNK2, but cannot explain the increased variability in HeLa cells compared with Rpe1 cells. (B) Schematic demonstrating how synthesis rate fluctuations, in this case transcriptional bursting, together with differential isoform lifetimes can lead to FIA fluctuations and thus increase FIA variability. (C) Measurements of isoform lifetimes show differential isoform stability primarily for MKNK2. Data represent values from a fitted curve+-s.e.m. (D) Measured total cytoplasmic mRNA abundance variability is greater than that predicted in the absence of synthesis rate fluctuations (see Materials and methods and Supplementary Theory ). ( E ) Total cytoplasmic mRNA, but not FIA, is correlated with DAPI intensity. ( F - H ) SRSF1 knockdown causes a large increase in FIA variability beyond the theoretical minimum (binomial isoform partitioning). Efficient knockdown of SRSF1 was confirmed by western blotting (F), and led to decreased isoform 1 abundance and increased isoform 2 abundance (G). (H) FIA variability compared with binomial isoform partitioning. Bars in (D, E, G, and H) represent mean+-s.d. ( n =3). Source data is available for this figure at www.nature.com/msb . Source Data for Figure 6

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Co-immunoprecipitation and co-localization of RRP1B with SRSF1 and CROP A. Western blot analysis of co-immunoprecipitation of endogenous RRP1B and SRSF1. B. Co-immunofluorescence of full-length HA-tagged RRP1B and endogenous SRSF1. Scale bar measures 10 muM. C. Co-immunoprecipitation of HA-tagged RRP1B constructs with endogenous SRSF1 and CROP. Lysates from 293T cells transfected with HA-tagged RRP1B were incubated with anti-HA for immunoprecipitation and blotted with anti-SRSF1 or anti-CROP. D. Co-immunofluorescence of full-length HA-tagged RRP1B and endogenous CROP. Scale bar measures 10 muM.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Inhibition of transcription enhances the interaction between RRP1B and SRSF1 A. Co-immunoprecipitation of RRP1B and SRSF1 with DRB or Act D treatment. 293T cells treated with DMSO, 25 mug/mL DRB, or 2.5 mug/mL and 5 mug/mL Act D as indicated were used for immunoprecipitation with anti-RRP1B. Normal rabbit IgG was used as a negative control. B. Co-immunofluorescence of RRP1B and SRSF1 after DMSO or 25 mug/mL DRB treatment. 293T cells were treated with 2 h DMSO or DRB and collected for immunofluorescence. Co-localization was confirmed using confocal fluorescence microscopy. Scale bar measures 10 muM.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Srsf1 depletion inhibits growth of human colorectal cancer-derived organoids. a A sample of cores taken from a human colon cancer tissue microarray (TMA), with the same respective core stained for SRSF1 or PROX1 on different sections. Scale bar 500 um. b Linear regression analysis showing the correlation of SRSF1 and PROX1 staining (based on histoscore) on the TMA shown in a , with each datapoint representing a core taken from a patient. c Relationship between SRSF1 immunohistochemistry staining and tumour stage in human patients, using TMA CO2081b, n = 54 vs 56 biologically independent tumour cores. d Representative images of patient-derived organoids (PDOs) treated with control or Srsf1 shRNAs. MD175 (polyp), MD20853 (CRC), MD20910 (CRC), MD19648 (FAP rectum Tumour), MD20043 (rectal carcinoma), C-002 (liver metastasis). Scale bar 1000 um. e Number of surviving organoid clones after shRNA treatment and f size of indicated PDOs, n = 3 vs 3 independent experiments. g Viability of PDO MD20043 after Srsf1 shRNA treatment and h mRNA expression (qPCR) of indicated genes, n = 3 vs 3 independent experiments. i Model outlining the role of SRSF1 in modulating tumour cell plasticity and invasion in colorectal cancer. Data in bar charts are represented as mean and error bars are SD with data analysed with two-tailed, unpaired t- tests, p values are indicated in figure panels. All biological replicates are shown as individual value plots and n > 3. See also Figure S7 .